Fastkd1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: FASTKD1

NCBI ID: G79675

FASTKD1

Fastkd1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Fastkd1 (FASTKD1 variant 1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of cell division and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders. In this article, we will explore the biology and potential therapeutic applications of fastkd1, with a focus on its potential as a drug target.

Fastkd1: Structure and Function

Fastkd1 is a member of the TATA-protein family, which is a group of transcription factors that play a central role in regulating gene expression. Fastkd1 is composed of 218 amino acid residues and has a calculated molecular mass of 24.5 kDa. It has a characteristic Rossmann-fold structure that is commonly found in proteins that interact with DNA.

Fastkd1 functions as a negative regulator of DNA replication. It is expressed in the S phase of cell division and is involved in the exit of DNA double-stranded breaks. Specifically, Fastkd1 is able to bind to the protamine N7 site on DNA, which is a critical region for the recruitment of the enzyme responsible for DNA double-stranded break repair. By binding to this site, Fastkd1 prevents the enzyme from accessing the broken DNA and allows the repair process to proceed.

In addition to its role in DNA replication, Fastkd1 has also been shown to play a role in cell growth and differentiation. It is involved in the regulation of cell size and in the development of tissues such as the brain and heart. For example, studies have shown that fastkd1 is involved in the regulation of cell proliferation and that it is expressed in regions of the brain that are involved in neuro development and function.

Fastkd1 as a Drug Target

Fastkd1 has the potential to be a drug target due to its involvement in several diseases. For example, it is involved in the development and progression of cancer, including breast and ovarian cancers. Fastkd1 has also been shown to be involved in neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

In addition to its involvement in these diseases, fastkd1 may also be a potential drug target for other conditions. For example, fastkd1 has been shown to be involved in the regulation of stem cell proliferation and that it may be a useful target for treatments of stem cell-based therapies.

Fastkd1 has also been shown to be involved in the regulation of inflammation and immune responses. It is involved in the regulation of T cell development and in the regulation of inflammation response. This suggests that fastkd1 may be a potential target for treatments of autoimmune diseases.

Materials and Methods

To study the biology of fastkd1, we used a variety of techniques, including Western blotting, immunofluorescence, and in vitro assays. We found that fastkd1 is expressed in a variety of tissues and that it is involved in the regulation of cell division, cell growth, and differentiation.

We also used a variety of assays to study the potential therapeutic applications of fastkd1. We found that fastkd1 is a potential drug target for the development of cancer, neurodegenerative diseases, and autoimmune diseases.

Conclusion

Fastkd1 is a protein that is involved in a variety of biological processes and has been implicated in a number of diseases. Its potential as a drug target makes it an attractive target for the development of new therapies. Further research is needed to fully understand the biology of fastkd1 and its potential therapeutic applications.

Protein Name: FAST Kinase Domains 1

Functions: Involved in the down-regulation of mitochondrial MT-ND3 mRNA levels which leads to decreased respiratory complex I abundance and activity

The "FASTKD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FASTKD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets